🔑 Key Takeaways

• Recent approvals and pipeline focus: Two EB gene therapies, Vyjuvek (2023) and Zevaskyn (2025), were approved within 12 months, both targeting RDEB. Most late-stage programs continue to focus on RDEB/DEB.
• Significant unmet need across subtypes: Despite 149 registered trials and 37 active studies, major subtypes such as JEB, EBS, DDEB, and Kindler syndrome still lack approved therapies. EBS has the largest patient population but a very limited pipeline.
• Regulatory and development challenges evolving: Strong clinical data alone is no longer sufficient. Manufacturing and CMC readiness have become critical approval factors, as highlighted by recent regulatory outcomes.
• Emerging strategic opportunities: Platform-based expansion, SCC prevention in RDEB, and leveraging patient registries and networks are becoming key differentiators in EB development.

Two gene therapy approvals. Twelve months. One disease that had almost no treatment options just three years ago. That is where Epidermolysis Bullosa (EB) stands today. The field has moved fast. But the work is far from over, and the most important opportunities may still lie ahead.

What Is Epidermolysis Bullosa?

Epidermolysis Bullosa is a group of rare, inherited skin disorders. The defining feature is extreme skin fragility. Minor friction, such as a hug, a shoe, or a bedsheet, can cause the skin to blister and tear. Around 500,000 people worldwide live with EB.

EB comprises four main subtypes. Epidermolysis Bullosa Simplex (EBS) results from mutations in keratin proteins that affect the outer skin layer. Junctional EB (JEB) arises when proteins at the skin’s junction layer fail. Dystrophic EB (DEB) occurs due to insufficient production of functional type VII collagen. Kindler EB is characterized by fragility across multiple skin layers, often accompanied by photosensitivity.

Recessive Dystrophic EB (RDEB) carries the heaviest burden. Patients develop chronic wounds that rarely heal. Scarring fuses fingers together. Esophageal strictures make swallowing painful. Most critically, more than half of RDEB patients develop aggressive squamous cell carcinoma (SCC) by mid-adulthood. SCC is the leading cause of death in RDEB.

Most EB patients across JEB, EBS, and Kindler EB still have no approved disease-modifying therapy.

Two Approvals That Changed the EB Landscape

In May 2023, the FDA approved Vyjuvek (beremagene geperpavec) from Krystal Biotech. It was the first topical gene therapy approved for any disease. Vyjuvek uses an HSV-1 viral vector to deliver the COL7A1 gene directly to wound sites. Physicians apply it topically, without surgery.

Then, in 2025, the FDA approved Zevaskyn (EB-101) from Abeome. This ex vivo cell-gene therapy takes a patient’s own skin cells, corrects the genetic defect in the lab, and grafts the repaired cells onto wounds. The pivotal VIITAL Phase 3 study demonstrated durable wound healing responses lasting well beyond the primary endpoint.

Both therapies target RDEB. Together, they prove that gene correction of a structural skin protein is achievable, safe, and durable. However, they also highlight a significant gap. Most EB patients across JEB, EBS, Dominant Dystrophic EB, and Kindler EB still have no approved disease-modifying therapy.

Key fact: Vyjuvek and Zevaskyn both target Recessive Dystrophic EB. JEB, EBS, DDEB, and Kindler EB remain largely unaddressed by approved therapies as of March 2026.

The EB Pipeline: What Is in Development Now

ClinicalTrials.gov lists 149 registered studies in Epidermolysis Bullosa. Thirty-seven are currently active. The pipeline spans multiple therapeutic approaches:

• Gene therapy: Krystal Biotech’s KB803 entered Phase 3 in 2025 for corneal abrasions in DEB — the first targeted ocular therapy for the condition. CHU de Quebec is beginning a Phase 1/2 study of a genetically modified self-assembled skin substitute (GMEB-SASS) for RDEB.
• Cell therapy: Castle Creek Biosciences completed a Phase 3 pivotal study for dabocemagene autoficel (D-Fi), an autologous fibroblast therapy for RDEB, with a BLA submission anticipated. RHEACELL is running two large Phase 3 trials of its ABCB5-positive mesenchymal stromal cell product (allo-APZ2-OTS) for EB, enrolling 91 patients across 16 international sites.
• Topical and small molecule agents: TCP-25 from Xinnate AB targets wound inflammation in DEB and JEB, with a Phase 2 study recruiting at 6 sites. TWi Biotechnology’s diacerein 1% ointment (AC-203) is in a Phase 2/3 study specifically for Generalized EBS at 36 sites worldwide. Paradigm Therapeutics is relaunching SD-101 dermal cream in a new Phase 3 starting May 2026.
• Antibody approaches: Two programs at Stanford explore immune-mediated approaches to DEB, one using IV immunoglobulin to reduce collagen VII antibodies, another using efgartigimod to target the same mechanism through FcRn inhibition.

The pipeline is broader than most observers expect. However, the majority of late-stage activity still concentrates in RDEB. Subtypes like JEB and EBS are gaining attention, but they lag significantly behind.

The Subtypes That the Field Still Overlooks

JEB is the most underserved subtype with existing scientific proof-of-concept. A landmark 2017 study published in Nature demonstrated dramatic wound healing through ex vivo gene correction in a JEB patient, yet no sponsor has industrialized this approach. TCP-25, in Phase 2 for both DEB and JEB, represents one of the few serious attempts to develop a therapy across JEB specifically.

EBS affects the largest patient population of any EB subtype. Yet it has historically attracted the least development investment. The EBShield study (AC-203 by TWi Biotechnology) and BioMendics’ TolaSure Gel, which targets aggregated mutant keratin rather than downstream wound healing, are the most advanced EBS-specific programs. Their results will define whether developers treat EBS as a real commercial priority or continue to overlook it.

Kindler EB has essentially no active programs. It is rare and mechanistically less understood. However, that also means there is almost no competition. A sponsor willing to invest in Kindler EB biology faces a relatively open field.

What Developers Must Get Right Beyond the Clinic

Clinical data alone no longer guarantee approval in gene therapy. The Ultragenyx UX111 program for MPS IIIA (Sanfilippo Syndrome) received a Complete Response Letter from the FDA in July 2025. The FDA described the neurodevelopmental outcomes as robust. However, the agency identified manufacturing process observations from a facility inspection, chemistry, manufacturing, and controls (CMC) issues as the reason for the delay.

Ultragenyx resubmitted the BLA in January 2026, and the FDA set a PDUFA date in Q3 2026. The episode carries a clear lesson: manufacturing validation is now a co-equal risk alongside clinical data. For EB programs built on autologous or ex vivo cell therapies, where each batch is patient-specific, manufacturing complexity is especially acute.

Sponsors should also invest in outcome measure standardization. The EB Disease Activity and Scarring Index (EBDASI) is gaining adoption as a composite measure. However, assessment approaches still vary across trials. Consistent, well-validated outcome measures reduce regulatory friction and make cross-trial comparisons more reliable.

Manufacturing validation is now a co-equal risk alongside clinical data in EB gene therapy.

Strategic Opportunities in Epidermolysis Bullosa

RDEB will become more competitive. Vyjuvek’s commercial presence, Zevaskyn’s approved ex vivo approach, D-Fi’s pending BLA, and multiple MSC programs in Phase 3 all compete for a small patient population. Real-world durability data from Vyjuvek will influence prescribing patterns over the next 18 to 24 months.

In contrast, JEB and EBS offer significant white space. JEB has an established scientific rationale and almost no late-stage competition. EBS has scaled more patients than any other EB subtype, and a pipeline that has barely scratched the surface of the available biology. Both subtypes present meaningful opportunities for sponsors willing to invest.

Patient advocacy accelerates development timelines in EB. DEBRA International and its national affiliates fund early-stage research, operate patient registries, and help sponsors design better trials. Developers who build genuine partnerships with DEBRA organizations recruit faster and reduce the design errors that slow programs down.

Click here for details on Epidermolysis Bullosa – Clinical Trial Feasibility

Conclusion: The Next Chapter in EB Treatment

Epidermolysis Bullosa has reached a genuinely historic moment. Two approved gene therapies have validated the science and established that serious development is possible in this space. However, the majority of EB patients still lack approved disease-modifying therapy. The pipeline is active and diverse, but the gap between early-stage innovation and late-stage development remains real.

The sponsors who succeed in Epidermolysis Bullosa will combine strong clinical data with proactive manufacturing investment, validated outcome measures, and deep engagement with the patient community. The approvals of 2023 and 2025 opened the door. The most meaningful progress for JEB, EBS, and the patients who have waited longest still lies ahead.

---

Need Support in Rare Disease Clinical Research for Epidermolysis Bullosa (EB)?

Rare diseases, such as Epidermolysis Bullosa (EB), present unique challenges across the clinical development continuum, from early-stage strategy and study design to the planning and execution of clinical trials. These challenges are often heightened by limited patient populations, evolving regulatory requirements, and gaps in clinical and real-world data.

With extensive experience supporting organizations in the rare disease space, our team can assist at various stages of development, including strategic insights, feasibility assessments, and clinical trial execution.

If you would like to discuss specific requirements or explore potential areas of support for EB or other rare diseases, please share your details using the form below. Our team will carefully review your request and connect with you promptly.

---